aTyr Pharma to Webcast Conference Call Reporting Third Quarter 2022 Financial Results

Rhea-AI Summary

aTyr Pharma (Nasdaq: LIFE) announced its plan to report Q3 2022 financial results and provide a corporate update on November 10, 2022, after market close. The company will host a conference call and webcast at 5:00 PM EST to discuss the results and operational updates. aTyr focuses on developing first-in-class medicines through its proprietary tRNA synthetase biology platform, with its lead candidate, efzofitimod, aimed at treating fibrotic lung disease.

Positive

• Management will provide a corporate update and financial results after Q3 2022.
• Focus on efzofitimod, designed to treat fibrotic lung disease, could signify potential market opportunities.

Negative

• None.

Management to host conference call and webcast on November 10th at 5:00 pm EST / 2:00 pm PST

SAN DIEGO, Nov. 03, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase biology platform, today announced that it will report third quarter 2022 financial results and provide a corporate update after the market close on Thursday, November 10, 2022. Management will host a conference call and webcast to review the results and provide an operational update.

Conference Call and Webcast Details:
Date: Thursday, November 10, 2022
Time: 5:00 p.m. EST / 2:00 p.m. PST
Dial-In Registration: https://register.vevent.com/register/BI4b50025644f64e129d555aeb8993aeb1
Webcast Registration: http://investors.atyrpharma.com/events-and-webcasts

Participants who wish to join the conference call by telephone must register at the above dial-in registration link in order to receive the dial-in number and a personalized PIN code that will be required to access the call. Participants may join the live webcast by accessing it at the above webcast registration link on the aTyr Events page. For more information or questions, please contact aTyr’s investor relations team at investorrelations@atyrpharma.com.

About aTyr

aTyr is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase biology platform. aTyr’s research and development efforts are concentrated on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. aTyr has built a global intellectual property estate directed to a potential pipeline of protein compositions derived from 20 tRNA synthetase genes and their extracellular targets. aTyr’s primary focus is efzofitimod, a clinical-stage product candidate which binds to the neuropilin-2 receptor and is designed to downregulate immune engagement in fibrotic lung disease. For more information, please visit http://www.atyrpharma.com.

Contact:
Ashlee Dunston
Director, Investor Relations and Corporate Communications
adunston@atyrpharma.com

FAQ

What is the date of aTyr Pharma's Q3 2022 conference call?

The conference call is scheduled for November 10, 2022.

What time will aTyr Pharma release its Q3 2022 financial results?

The financial results will be released after market close on November 10, 2022.

What is the primary focus of aTyr Pharma's drug development?

aTyr Pharma focuses on developing first-in-class medicines using its proprietary tRNA synthetase biology platform.

What is efzofitimod?

Efzofitimod is a clinical-stage product candidate aimed at downregulating immune engagement in patients with fibrotic lung disease.